FAQ: HeartBeam Inc. Wins 2025 Innovation Award for Remote Cardiac Diagnostics

What is HeartBeam Inc.?

HeartBeam Inc. is a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, through innovative technologies like its cable-free 12-lead ECG device.

Why did HeartBeam Inc. win the 2025 Innovation Award?

HeartBeam won the award for its FDA-cleared 3D ECG technology that enables clinical-grade arrhythmia diagnostics in non-clinical settings, showcasing its leadership in remote cardiac care.

How does HeartBeam’s technology work?

HeartBeam’s technology captures the heart’s electrical signals from three dimensions using a compact, cable-free device, allowing for actionable heart intelligence outside of medical facilities.

What are the implications of HeartBeam’s technology for cardiac care?

This technology redefines cardiac health management by enabling physicians to identify cardiac health trends and acute conditions outside medical facilities, thus improving accessibility and convenience for patients.

When is HeartBeam’s synthesized 12-lead ECG software expected to be commercialized?

The synthesized 12-lead ECG software is under FDA review, with commercialization planned upon clearance.

Where can I find more information about HeartBeam Inc.?

For more information, visit www.HeartBeam.com or the company’s newsroom at https://ibn.fm/BEAT.

Who can benefit from HeartBeam’s technology?

Patients requiring cardiac monitoring and physicians seeking to provide remote cardiac care can benefit from HeartBeam’s innovative technology.

What awards has HeartBeam received?

HeartBeam has received the 2025 Innovation Award in Remote Cardiac Diagnostics from the Medical Device Network Excellence Awards, among other accolades for its contributions to remote cardiac care.

How can I stay updated on HeartBeam Inc. news?

To stay updated, visit the company’s newsroom at https://ibn.fm/BEAT or sign up for alerts from BioMedWire.